NEW YORK (GenomeWeb) – Voyager Therapeutics this week announced that it has licensed the non-exclusive rights to use Regenx Biosciences' proprietary adeno-associated viral vectors in three of its drug-development programs, including one focused on an expressed RNAi treatment for monogenic amyotrophic lateral sclerosis (ALS).

The arrangement also gives Voyager rights to use Regenx's vectors to develop therapies for Friedreich's ataxia and Huntington's disease (HD).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.